Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

cepharm.com" target="_new">http://www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding: the timeframes in which Cadence expects to complete enrollment in, and announce the results of, clinical trials of its product candidates; the timeframes in which Cadence anticipates filing submissions with regulatory authorities seeking marketing authorizations for its product candidates; the expected impact of clinical trial results on the market and clinical value of Cadence's product candidates; and the potential for Cadence's product candidates to address unmet medical needs. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: the outcomes of final analyses of data from Cadence's clinical trials of its product candidates may vary from the company's initial analyses, and the FDA may not agree with Cadence's interpretation of such results; the company's clinical trials may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials; Cadence may experience delays in completing its clinical trials or achieving its product development goals, or experience problems with the designs or execution of its clinical trials; the company may decide, or be required by FDA, to expand or modify its ongoing clinical trials or conduct additional clinical trials in order to support applications for market approval of its product candidates; the market demand for Cadence's product candidates, and their ability to compete with new or existing products, may be less than anticipated; the company's product
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 12, 2011 Mylan Inc. (Nasdaq: MYL ... president of Dey Pharma, L.P., Mylan,s fully integrated specialty ... 20 years of professional experience in strategic product launches, ... he served as president and chief executive officer of ...
... Inc. (NYSE Amex: INO ), which is advancing ... that Dr. J. Joseph Kim, President and CEO, will present ... Healthcare Conference taking place December 13-14 at the Waldorf-Astoria in ... 13 10:50 am ET A live and archived ...
Cached Medicine Technology:Mylan Names John Thievon President of Dey Pharma 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... 22, 2015 JJsHouse.com is a famous dress ... the business announces its latest collection of wedding dresses ... most important issue is the wedding dress on your big ... a woman’s life. Every bride wants to find the most ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... are invited to attend and cover the 2008 ... be held March 16-19, 2008, at the Hyatt ... organized by the Centers for Disease Control and ... Council of State and Territorial Epidemiologists, the Association ...
... It seems to plug calcium leaks that cause tiring ... News) -- An experimental drug may help fatigued athletes ... say physiologists at Columbia University Medical Center. , Tests ... regimens, tiny leaks of calcium continuously enter the muscle ...
... Johns Hopkins researchers from the Whiting School of Engineering and the ... on a chip - designed to mimic the chemical complexities of ... cells in the brain work together to form the nervous system. ... story in the February 2008 issue of the British journal Lab ...
... Tribune has published a,feature story on the terrible incidence ... loving dog owners, and treatments and scientific,research under way ... of release.,Morris Animal Foundation (MAF) is cited as leading ... 10 to 20 years. MAF can help provide the,press ...
... (WASHINGTON, February 12, 2008) A new study demonstrates for ... to create functional immune system blood cells, a finding which ... cells as an alternative source of cells for bone marrow ... and immune disorders, who need these transplants for treatment, was ...
... VEGAS, Feb. 12 For years, celebrities and,socialites ... products, including,toothpaste. Now, however, U.S. suburbanites and urban ... local drugstore to enjoy luxurious French oral,care., ... toothpaste in France for more than three,decades, has ...
Cached Medicine News:Health News:2008 International Conference on Emerging Infectious Diseases 2Health News:Muscle Fatigue Drug May Fight Heart Failure 2Health News:'Lab on a chip' mimics brain chemistry 2Health News:A functional immune system can be derived from embryonic stem cells, preliminary study finds 2Health News:A functional immune system can be derived from embryonic stem cells, preliminary study finds 3Health News:A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
Foam Cervical Collar is medium-firm density. Breathable. Deeply anatomically contoured. Natural color, 100% cotton stockinette-covered for comfort. 2" hook and loop closures are another mark of quali...
... Ezy Wrap® Economy Universal ... foam with synthtic white ... reversed for flexion or ... wash, air dry. 3"H.,Universal ...
Medicine Products: